Syncom Formulations (India) Ltd

As of 24-Nov, Syncom Formulations (India) Ltd’s stock price has fallen to ₹15.50, down 2.27% on the day, continuing a downward trend that has seen the share price decline by 6.57% over the past week. This underperformance contrasts sharply with broader market indices and reflects a complex interplay of recent financial results, valuation concerns, and long-term growth challenges.

As of November 18, 2025, Syncom Formul. is fairly valued with a PE ratio of 24.53, compared to its peers like Sun Pharma at 36.56 and Cipla at 22.49, indicating reasonable pricing relative to its earnings growth potential despite underperforming the Sensex year-to-date.

As of November 14, 2025, Syncom Formul. is considered overvalued with a valuation grade of expensive, reflected by a PE ratio of 24.77 and underperformance of -20.15% compared to the Sensex's 9.00%.

As of November 14, 2025, Syncom Formul. is considered overvalued with a PE ratio of 24.77 and an EV to EBITDA ratio of 21.23, both higher than its peers, despite a strong long-term return of 802.17% and a recent year-to-date decline of 17.00%.

As of November 14, 2025, Syncom Formul. is considered overvalued with a valuation grade of expensive, reflected by a PE ratio of 24.77 and a year-to-date return of -17.00%, despite outperforming the Sensex recently.

As of November 13, 2025, Syncom Formulations is considered very expensive and overvalued, with a PE Ratio of 25.08 and other elevated valuation metrics compared to peers, while its year-to-date return of -15.95% significantly lags behind the Sensex's 8.11%.

Syncom Formul. has experienced significant fluctuations in financial performance, with net sales increasing to 465.01 Cr in March 2025 from 263.39 Cr in March 2024, but down from a peak of 21,966.32 Cr in March 2022. Despite recent improvements in key metrics, the company's historical data reflects volatility.

As of November 4, 2025, the market trend has shifted to a moderate bearish stance, driven by bearish MACD, Bollinger Bands, moving averages, and KST indicators, despite a mildly bullish signal from Dow Theory.

As of November 4, 2025, Syncom Formul. has shifted to a bearish trend, supported by negative indicators such as a bearish MACD, Bollinger Bands, and moving averages, despite a mildly bullish signal from Dow Theory.

As of November 3, 2025, Syncom Formul. shows a mildly bearish trend due to bearish signals from the MACD and KST, despite a bullish weekly RSI, indicating a cautious approach is warranted.

As of 29 September 2025, Syncom Formul. is in a bearish trend, indicated by a bearish MACD, RSI, Bollinger Bands, daily moving averages, and KST across multiple time frames, reflecting significant market weakness.

As of September 29, 2025, Syncom Formul. is considered overvalued with a valuation grade of expensive, reflected by its PE Ratio of 26.64 and underwhelming year-to-date return of -18.50%, despite being lower than some peers like Sun Pharma and Divi's Lab.

As of 29-Sep, Syncom Formulations (India) Ltd's stock price is 16.30, down 2.45%, and has declined 9.8% over the past week, underperforming its sector. Despite positive quarterly results, the company faces long-term growth challenges and high valuations, contributing to a significant drop in investor confidence and a yearly return of -25.84%.

As of September 26, 2025, the technical trend for Syncom Formul is mildly bearish, indicated by bearish signals from MACD, moving averages, KST, and OBV, despite some mixed signals from Bollinger Bands and Dow Theory.